Could a cystic fibrosis drug ease stubborn sinus infections?
NCT ID NCT03439865
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether ivacaftor, a drug used for cystic fibrosis, can help people with chronic sinusitis caused by hard-to-treat bacteria. Twenty adults will receive either ivacaftor plus standard care or standard care alone for 14 days. Researchers will check safety, symptom scores, and infection markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivacaftor (Kalydeco)
- What this could lead to
- If it works, this could point toward a new treatment option for chronic sinus infections that don't respond to standard care.
- What could go wrong
- This is a very early, small pilot study with only 20 people. It may not show clear benefits, and ivacaftor is not yet proven for this condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS (DIAGNOSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sugar alcohol rinse could soothe sinus pain in cystic fibrosis
- Could viruses and epigenetics be the hidden cause of chronic sinusitis?
- New sinus implant aims to unblock noses and ease facial pain
- Sinus study pulled before it even started
- Scientists hunt for hidden bacteria behind chronic sinusitis
- Can a nerve block make sinus surgery less bloody?